Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Asset Writedowns and Impairment (2024)

Historic Asset Writedowns and Impairment for Arcus Biosciences (RCUS) over the last 1 years, with Q1 2024 value amounting to $20.0 million.

  • Arcus Biosciences' Asset Writedowns and Impairment changed N/A to $20.0 million in Q1 2024 from the same period last year, while for Dec 2024 it was $20.0 million, marking a year-over-year change of. This contributed to the annual value of $20.0 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Arcus Biosciences reported Asset Writedowns and Impairment of $20.0 million as of Q1 2024.
  • Arcus Biosciences' Asset Writedowns and Impairment's 5-year high stood at $20.0 million during Q1 2024, with a 5-year trough of $20.0 million in Q1 2024.